- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00756262
Probiotic Lactobacillus GG to Eliminate VRE Colonization (VRE)
The use of LGG will be associated with elimination of VRE colonization.
The primary comparison will be VRE elimination rates among those patients that receive LGG compared to those that receive placebo. The primary endpoint will be the proportion of patients with VRE at one week after cessation of administration of study medication or placebo. The investigators assume that the placebo group will have very little spontaneous elimination of VRE and that the LGG group will be more likely to have eliminated VRE colonization at the end of one week.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center-Division of Geographic Medicine and Infectious Diseases
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age greater than or equal to 18 years
- Identified as having had a clinical isolate or stool or rectal swab culture positive for VRE
- Able to give informed consent and report on side effects
- Tolerating an oral/enteral diet
- Stable comorbid conditions
- Willing and able to come to Tufts for weekly visits
- Outpatient
Exclusion Criteria:
- Inpatients
- Active infection with VRE being treated
- Pregnancy
- Known use of LGG or another probiotic (not including yogurt) within the previous 30 days
- Presence of an active bowel leak, acute abdomen, active intestinal disease, or significant bowel dysfunction
- Presence of an absolute neutrophil count less than 500 per cubic mm or anticipation post chemotherapy that the absolute neutrophil count will fall below 500 per cubic mm
- History of adverse reaction to product containing lactobacillus
- Active colitis (see definition below)
- Treatment with an antibiotic with activity against VRE
- Life expectancy less than one year or life-threatening condition
- Known or suspected allergies to probiotics, lactobacillus, milk protein, and microcrystalline cellulose
- Structural heart disease, history of endocarditis or valve replacement
- Positive baseline stool culture for LGG
- Recent or planned chemotherapy or radiation therapy
- Solid organ transplant within the prior year
- Stem cell transplant within the prior year
- On active immunosuppressive medication [anti-rejection, injectable immunosuppressive drugs for autoimmune disease, or corticosteroids (greater than 1/2 mg per kg body weight of prednisone or its equivalent) not including inhaled or topical steroids]
- Allergy or intolerance to or contraindication to two or more of the rescue antibiotic regimens (ampicillin, clindamycin, moxifloxacin)
Colitis will be defined as a history of Crohn's disease or ulcerative colitis with active diarrhea, active diarrhea due to Clostridium difficile infection, active diarrhea due to known or unknown cause with a stool specimen showing fecal leukocytes (if none has been done in such a patient this will be requested prior to enrollment). Diarrhea will be defined as more than three unformed bowel movements per day. The subject's primary physician will be asked to assess the subject's life expectancy, and subjects with an estimated life expectancy of less than one year as judged by the physician who knows him or her best will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Lactobacillus rhamnosus LGG
|
Drug to be administered orally (capsule form).
Dose=2 capsules/day for 14 days.
Dosage strength= 1x10^10 bacteria
Other Names:
|
Placebo Comparator: 2
Microcrystalline cellulose capsules
|
Drug to be administered orally (capsule form).
Dose=2 capsules/day for 14 days.
Dosage strength= 1x10^10 bacteria
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary endpoint will be the proportion of patients with VRE at one week after cessation of administration of study medication or placebo.
Time Frame: Day 21post enrollment
|
Day 21post enrollment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The rate of VRE colonization in LGG recipients versus controls at 2 weeks and 6 weeks post discontinuation of administration of LGG or placebo.
Time Frame: 2 weeks, and 6 weeks
|
2 weeks, and 6 weeks
|
The rate of LGG colonization in study population receiving LGG compared to placebo.
Time Frame: days 21, 28, 56
|
days 21, 28, 56
|
That LGG can be used safely and without significant side effects in both hospitalized and ambulatory patients.
Time Frame: day 0-56 and 6 mnths
|
day 0-56 and 6 mnths
|
That among those treated with LGG, the colony counts of VRE will be lower when compared to controls even among those in whom colonization is not eliminated.
Time Frame: day 0,7,14,21,28,56
|
day 0,7,14,21,28,56
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 6283
- 5 R 21 AT-001892
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vancomycin Resistant Enterococcal Colonization
-
Intralytix, Inc.RecruitingVancomycin-Resistant Enterococcal ColonizationUnited States
-
Oregon Health and Science UniversityTerminatedGI Colonization of Vancomycin-resistant EnterococcusUnited States
-
The Methodist Hospital Research InstituteM.D. Anderson Cancer Center; National Institute of Allergy and Infectious Diseases... and other collaboratorsRecruitingAntibiotic Resistant Infection | Clostridium Difficile | Antimicrobial Drug Resistance | Carbapenem-Resistant Enterobacteriaceae Infection | Vancomycin Resistant Enterococci Infection | Vancomycin-Resistant Enterococcal Infection | Carbapenem Resistant Bacterial Infection | Extended Spectrum Beta-Lactamase...United States
-
Chuncheon Sacred Heart HospitalRecruitingCarbapenem-Resistant Enterobacteriaceae Infection | Vancomycin-Resistant Enterococcal InfectionKorea, Republic of
-
Taipei Medical University Shuang Ho HospitalTaipei Medical University; Delta ElectronicsUnknownProbiotics | Vancomycin-Resistant EnterococciTaiwan
-
University Hospital, Clermont-FerrandUnknownVancomycin Resistant Enterococcus Intestinal CarriageFrance
-
Chuncheon Sacred Heart HospitalSeverance Hospital; National Institute of Health, KoreaRecruitingCarbapenem-Resistant Enterobacteriaceae | Vancomycin (Glycopeptide) Resistant Enterococcus (VRE)Korea, Republic of
-
University of CologneUniversity Hospital Tuebingen; University Hospital Freiburg; Universitätsklinikum... and other collaboratorsUnknownCancer | Vancomycin (Glycopeptide) Resistant Enterococcus (VRE)
-
Kaleido BiosciencesTerminatedVancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized SubjectsUnited States
-
Emory UniversityCenters for Disease Control and PreventionNot yet recruitingMulti-Drug Resistant Organism ColonizationUnited States
Clinical Trials on Lactobacillus GG or Culturelle
-
Children's Hospital Medical Center, CincinnatiWithdrawn
-
Chang Gung Memorial HospitalCompletedAsthma | Allergic Rhinitis | Atopic DermatitisTaiwan
-
University of OklahomaWithdrawnCOPD | Obstructive Lung DiseaseUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyTerminatedLymphoma | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative NeoplasmsUnited States
-
Medstar Health Research InstitutePatient-Centered Outcomes Research Institute; Georgetown University; Children...CompletedLower Urinary Tract SymptomsUnited States
-
Northwell HealthCompletedNon-Alcoholic Fatty Liver DiseaseUnited States
-
Washington University School of MedicineCenters for Disease Control and PreventionCompletedInfectious Disease of Digestive TractUnited States
-
Massachusetts General HospitalCompletedHealthy | ElderlyUnited States
-
University of Texas Southwestern Medical CenterNational Institute on Alcohol Abuse and Alcoholism (NIAAA); The Cleveland Clinic and other collaboratorsTerminatedAcute Alcoholic HepatitisUnited States
-
Massachusetts General HospitalCompletedHealthy | ElderlyUnited States